Lundbeckfond Ventures

Lundbeckfond Ventures is the wholly owned venture-investing entity of the Lundbeck Foundation, a Copenhagen-based commercial foundation that holds a controlling interest in pharmaceutical company Lundbeck A/S. The ventures team operates with an independent investment committee and a purely return-seeking mandate, distinct from the foundation's grant-making activities. Profits are recycled back into the foundation to fund future investments and scientific grants.

While the foundation's heritage and the parent pharmaceutical company focus heavily on brain health, Lundbeckfond Ventures invests more broadly across biotechnology, including oncology, immunology, and platform technologies. Its portfolio includes IO Biotech (immuno-oncology) and Nomic Bio (proteomics), showing a willingness to back therapeutics and tools outside strict neuroscience. However, neurodegeneration and psychiatry remain areas of deep internal expertise that the team leverages.

As an evergreen investor, the firm is not bound by the typical 8-to-10-year venture fund lifecycle. It can hold positions through clinical development, regulatory approval, and even IPO — treating each biotech investment as a long-duration bet. This time-horizon advantage is a core pitch to founding scientists and other long-term investors, distinguishing it from fund-cycle venture firms.

Lundbeckfond Ventures is willing and able to lead or co-lead seed and Series A rounds, typically working alongside other specialist life-science investors. The firm's permanent capital base allows it to deploy meaningful tranches into early-stage companies and then follow on aggressively in later rounds, often maintaining or increasing its pro-rata position through subsequent financings.

Managing Partner Mette Kirstine Agger leads the investment process, working alongside Partner Jacob Lange Moresco and the broader investment team in Copenhagen. Final investment decisions are made by the firm's independent investment committee, which operates separately from the Lundbeck Foundation's board and grants committees. The foundation appoints the committee members but does not direct individual investment choices.

Lundbeckfond Ventures does not raise outside funds. All investment capital comes from the Lundbeck Foundation's endowment, earned primarily through dividends from its ownership stake in Lundbeck A/S. This single-LP structure allows for a streamlined, patient approach without the reporting and alignment complexities of managing third-party capital.